Comparative Pharmacology
Head-to-head clinical analysis: ERYPED versus ERYTHROMYCIN ESTOLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYPED versus ERYTHROMYCIN ESTOLATE.
ERYPED vs ERYTHROMYCIN ESTOLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It is a macrolide antibiotic.
Erythromycin estolate is a macrolide antibiotic that reversibly binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step. It may also exhibit immunomodulatory and anti-inflammatory effects.
250–500 mg orally every 6 hours or 500–1000 mg intravenously every 6 hours; maximum 4 g/day.
250-500 mg orally every 6-12 hours
None Documented
None Documented
2-4 hours (prolonged to 4-6 hours in neonates and patients with hepatic impairment); requires q6h dosing for most indications.
Approximately 1.5-2 hours in normal adults; prolonged to 5-6 hours in end-stage renal disease.
Primarily hepatic (biliary excretion of unchanged drug and metabolites); approximately 5% renal excretion as unchanged drug.
Primarily hepatic via biliary excretion into feces; approximately 2-5% excreted unchanged in urine. <5% renal elimination.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic